Argenica Therapeutics (ASX:AGN) has completed the manufacturing of the ARG-007 drug required for Phase 2 clinical trials. The finalised, sterile drug product manufacturing will be completed by the end of the year keeping the Argenica on track for first patient dosing during Q1 CY24 | ASX Announcement: https://announcements.asx.com.au/asxpdf/20231214/pdf/05yjzbqmnd1b00.pdf $AGN #Phase2 #ClinicalTrials #shorts
PEK
0.325
170.8%
JAY
0.001
-50%
CHM
0.008
60%
LNR
0.001
-50%
AJL
0.008
33.3%
ECS
0.009
-25%
ATX
0.07
27.3%
ERL
0.003
-25%
EDU
0.165
26.9%
OSL
0.003
-25%
HCF
0.033
26.9%
RMY
0.026
-21.2%
SHP
0.005
25%
DTM
0.004
-20%
8CO
0.017
21.4%
HTA
0.02
-20%
EPM
0.006
20%
RDN
0.004
-20%
IPT
0.006
20%
ORD
0.41
-18%
MEM
0.006
20%
EVR
0.005
-16.7%
FRM
0.285
18.8%
KPO
0.005
-16.7%
H2G
0.013
18.2%
NWM
0.01
-16.7%
LMG
0.013
18.2%
ROG
0.005
-16.7%
PCL
0.013
18.2%
AZ9
0.027
-15.6%
RMI
0.013
18.2%
FFF
0.006
-14.3%
E79
0.027
17.4%
HHR
0.006
-14.3%
HE8
0.014
16.7%
KLI
0.03
-14.3%
1AE
0.074
15.6%
KNB
0.078
-14.3%
NIM
0.115
15%
PGY
0.006
-14.3%
